Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of telomerase activity, the catalysis of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1). Telomerases catalyze extension of the 3'- end of a DNA strand by one deoxynucleotide at a time using an internal RNA template that encodes the telomeric repeat sequence. [EC:2.-.-.-, GOC:ai]
Telomerase activity is tightly regulated to prevent uncontrolled cell proliferation and maintain genomic stability. The enzyme telomerase adds repetitive DNA sequences (TTAGGG) to the ends of chromosomes, known as telomeres, compensating for the loss that occurs during DNA replication. This process is essential for maintaining chromosome integrity and preventing cellular senescence.
**Regulation of Telomerase Activity:**
**1. Transcriptional Regulation:**
- **TERT (Telomerase Reverse Transcriptase) gene:** This gene encodes the catalytic subunit of telomerase. Its expression is tightly controlled and is generally low in most somatic cells.
- **Transcription factors:** Various transcription factors, including c-Myc, E2F1, and NF-κB, can bind to regulatory elements in the TERT gene, promoting its transcription in response to specific cellular signals.
- **Epigenetic modifications:** DNA methylation and histone modifications can influence TERT gene expression. For example, hypermethylation of the TERT promoter can suppress its transcription.
**2. Post-Translational Regulation:**
- **Protein stability:** Telomerase subunits are subject to ubiquitination and proteasomal degradation. This process ensures that telomerase activity is tightly regulated and prevents its accumulation.
- **Protein phosphorylation:** Phosphorylation events can affect the activity and stability of telomerase subunits.
**3. Subcellular Localization:**
- **Nuclear transport:** Telomerase must be transported from the cytoplasm to the nucleus to access telomeres. This process is regulated by specific nuclear localization signals (NLS) within telomerase subunits.
- **Association with telomeres:** Telomerase associates with telomeres through interactions with specific proteins, including TRF1 and TRF2, which are components of the shelterin complex.
**4. Cellular Signals:**
- **Growth factors:** Growth factors, such as epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), can stimulate telomerase activity.
- **Oxidative stress:** Reactive oxygen species (ROS) can induce telomerase expression, potentially as a protective mechanism against DNA damage.
- **Cellular senescence:** During replicative senescence, telomerase activity is typically downregulated, contributing to the cessation of cell division.
**5. Disease Implications:**
- **Cancer:** Dysregulation of telomerase activity is commonly observed in cancer cells, allowing them to evade senescence and proliferate indefinitely.
- **Aging:** Telomere shortening and reduced telomerase activity contribute to the aging process.
**Overall, the regulation of telomerase activity is a complex and multifaceted process involving transcriptional, post-translational, and cellular signaling mechanisms. This intricate regulation ensures proper telomere maintenance and cellular homeostasis, while also contributing to the pathogenesis of various diseases.**'
"
Protein | Definition | Taxonomy |
---|---|---|
Protein mono-ADP-ribosyltransferase PARP4 | A protein mono-ADP-ribosyltransferase PARP4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9UKK3] | Homo sapiens (human) |
Serine-protein kinase ATM | A serine-protein kinase ATM that is encoded in the genome of human. [PRO:CNA] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
pd 173074 | aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist | |
caffeine | purine alkaloid; trimethylxanthine | adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic | |
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source | chromones; morpholines; organochlorine compound | autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector |
pj-34 | PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties. | phenanthridines; secondary carboxamide; tertiary amino compound | angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent |
4-Methoxybenzamide | benzamides | ||
schizandrin b | schizandrin B: a phytogenic antineoplastic agent with anti-inflammatory activity; isolated from Schisandra plant | ||
thiourea | thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur. Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS. | one-carbon compound; thioureas; ureas | antioxidant; chromophore |
ku 55933 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source | ||
cgk 733 | diarylmethane | ||
nu 7026 | 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source | organic heterotricyclic compound; organooxygen compound | |
rucaparib | AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source | azepinoindole; caprolactams; organofluorine compound; secondary amino compound | antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor |
nu 7441 | 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source | dibenzothiophenes | |
veliparib | benzimidazoles | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
ku-0060648 | dibenzothiophenes | ||
dactolisib | dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment. dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR | imidazoquinoline; nitrile; quinolines; ring assembly; ureas | antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor |
ku 60019 | |||
olaparib | cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
niraparib | niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy. niraparib: structure in first source | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent |
cp 466722 | quinazolines | ||
(3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholine | indoles | ||
ve 821 | 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide: an antineoplastic agent; structure in first source | aromatic amide | |
torin 2 | torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties. | aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline | antineoplastic agent; mTOR inhibitor |
byl719 | proline derivative | ||
cc-115 | 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one: an mTOR kinase inhibitor; structure in first source | ||
vx-970 | berzosertib: an ATR kinase inhibitor | sulfonamide | |
etp-46464 | ETP-46464: inhibits ATM and Rad3-related kinase; structure in first source | ||
xav939 | XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group. XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source | (trifluoromethyl)benzenes; thiopyranopyrimidine | tankyrase inhibitor |
bmn 673 | talazoparib: inhibits both PARP1 and PARP2; structure in first source |